Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the differences in progression-free survival at 6 months in subjects with KRAS wild-type metastatic colorectal cancer receiving second line treatment (after failure of a previous irinotecan and 5FU based regimen) with panitumumab plus XELOX compared to the treatment with XELOX alone, without major safety problems
Critère d'inclusion
- metastatic colorectal cancer (mCRC)